IBIO Aktie

>IBIO Aktienkurs

1.59 EUR -5.9% (TradegateBSX)

Ask: 1.74 EUR / 2300 Stück

Bid: 1.69 EUR / 2400 Stück

Tagesumsatz: 355 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

IBIO Aktie über LYNX handeln

Intraday

1 Jahr

>IBIO Performance

1 Woche: +3,2%

1 Monat: -29,0%

3 Monate: -0,6%

6 Monate: +119,3%

1 Jahr: -54,8%

laufendes Jahr: +7,8%

>IBIO Aktie

Name:

IBIO INC. DL -,001

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US4510337086 / A3E2GR

Symbol/ Ticker:

0JV0 (Frankfurt)

Kürzel:

FRA:0JV0, ETR:0JV0, 0JV0:GR

Index:

Webseite:

https://ibioinc.com/

Profil:

iBio Inc. is a preclinical-stage biotechnology company developing next-generation biopharmaceuticals by leveraging artificial intelligence and advanced computational biology. The company focuses on creating novel antibody-based therapies for cardiome..
>Volltext..

Marktkapitalisierung:

59.25 Mio. EUR

Unternehmenswert:

15.72 Mio. EUR

Umsatz:

0.26 Mio. EUR

EBITDA:

-18.95 Mio. EUR

Nettogewinn:

-21.43 Mio. EUR

Gewinn je Aktie:

-0.87 EUR

Schulden:

2.12 Mio. EUR

Liquide Mittel:

24.84 Mio. EUR

Operativer Cashflow:

-16.14 Mio. EUR

Bargeldquote:

8.93

Umsatzwachstum:

-20%

Gewinnwachstum:

-28.15%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

IBIO

Letzte Datenerhebung:

04.04.26

>IBIO Kennzahlen

Aktien/ Unternehmen:

Aktien: 34.54 Mio. St.

Frei handelbar: 87.08%

Leerverk. Aktien: -

Rückkaufquote: -96.26%

Mitarbeiter: 20

Umsatz/Mitarb.: 0.02 Mio. EUR

Analysten:

Analystenrating: Strong buy

Kursziel: 171.04%

Bewertung:

KGV: -

KGV lG: -

KUV: 644.36

KBV: 1.05

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: -265.67%

Gewinnmarge: -8245.67%

Operative Marge: -7657.67%

Managementeffizenz:

Gesamtkaprendite: -57.47%

Eigenkaprendite: -70.22%

>IBIO Peer Group

Gesundheit, Antikörper- Behandlung, Diabetes- & Adipositas- Behandlung, Onkologie/ Krebs- Behandlung

>IBIO Chart & Kurs - Tradegate

>IBIO News

16.03.26 - 21:33	iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) (GlobeNewswire EN)
	Company to host corporate update call on Tuesday, March 17, at 4 p.m. ET Company to host corporate update call on Tuesday, March 17, at 4 p.m. ET...

09.03.26 - 12:06	iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss (GlobeNewswire EN)
	Study demonstrated reduction of 6.7% visceral fat and 5.2% total fat mass in obese non-human primates (NHPs) despite high-calorie diet Study demonstrated reduction of 6.7% visceral fat and 5.2% total fat mass in obese non-human primates (NHPs) despite high-calorie diet...

24.02.26 - 13:03

iBio to Participate in Upcoming Investor Conferences (GlobeNewswire EN)

SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), an AI-driven innovator of precision antibody therapies, today announced that Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer, and Felipe Duran, Chief Financial Officer, will participate in fireside chats at the Oppenheimer 36th Annual Healthcare Life Sciences Conference and the Leerink Global Healthcare Conference....

10.02.26 - 22:48	iBio GAAP EPS of -$0.09 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

10.02.26 - 22:09	iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update (GlobeNewswire EN)
	Secured $26 Million in PIPE Financing Led by a Top-Tier Biotech Investor to Advance Preclinical Programs and Extend Cash Runway...

02.02.26 - 17:30	iBio, Inc. (IBIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
	iBio (IBIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....

09.01.26 - 15:36	Privatplatzierung über 26 Mio. Dollar beflügelt Ibio-Aktie (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

09.01.26 - 14:00	iBio announces private placement financing to raise ~$26M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

09.01.26 - 13:03

iBio Announces $26 Million Private Placement (GlobeNewswire EN)

SAN DIEGO, Jan. 09, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced that it has entered into a securities purchase agreement with existing healthcare-focused, high-quality institutional investors for a private placement ("PIPE") financing that is expected to result in gross proceeds of approximately $26 million to the Company before placement agent fees and offering expenses. The offering is expected to close on or about January 13, 2026, subject to customary closing conditions....

24.11.25 - 22:18	iBio to Participate in the 8th Annual Evercore Healthcare Conference (GlobeNewswire EN)
	SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), an AI-driven innovator of precision antibody therapies, today announced that it will participate in the 8th Annual Evercore Healthcare Conference, taking place December 2–4, 2025, in Miami....

13.11.25 - 06:24	iBio GAAP EPS of -$0.11, revenue of $0.1M beats by $0.07M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

13.11.25 - 01:00	iBio, Inc. (IBIO) Reports Q1 Loss (Zacks)
	iBio (IBIO) delivered earnings and revenue surprises of -57.14% and 0.00%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?...

12.11.25 - 22:06	iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update (GlobeNewswire EN)
	Strengthened cash position and extended runway into the fourth quarter of fiscal year 2027 after closing underwritten public offering with up to potentially $100 million of total gross proceeds...

23.10.25 - 13:03	iBio to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference (GlobeNewswire EN)
	SAN DIEGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), an AI-driven innovator of precision antibody therapies, today announced that it will participate in the Guggenheim 2nd Annual Healthcare Innovation Conference, taking place November 10–12, 2025 in Boston....

23.10.25 - 10:30	Why Did iBio Shares Surge Over 11% In Pre-Market Trading? (Benzinga)
	iBio shares rose sharply after announcing upcoming presentations on its obesity treatment candidate at two industry conferences. read more...

21.10.25 - 13:03

iBio to Present New Preclinical Data on Its Activin E Antibody at Two Upcoming Scientific Conferences, ObesityWeek® and PEGS Europe 2025 (GlobeNewswire EN)

SAN DIEGO, Oct. 21, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced that Cory Schwartz, Ph.D., Director of Research and Early Development at iBio, will deliver an oral presentation at ObesityWeek 2025 November 4-7 in Atlanta. In addition, Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer of iBio, will deliver an oral presentation at PEGS Europe 2025 November 11–13 in Lisbon....

05.09.25 - 13:48	iBio GAAP EPS of -$1.75, revenue of $0.4M beats by $0.2M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

05.09.25 - 13:33	iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update (GlobeNewswire EN)
	SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced its financial results for the fiscal year ended June 30, 2025, and provided a corporate update on its progress....

25.08.25 - 13:03	iBio Announces Closing of $50 Million Public Offering (GlobeNewswire EN)
	Total gross proceeds of $100 million if all Series G warrants and Series H warrants are exercised for cash...

19.08.25 - 14:27	iBio prices $50M public offering (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Die Frauen bewundern einen Mann wegen seiner Stärke, aber sie lieben ihn wegen seiner Schwächen. - Beatrice Brown

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram